Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis ...Middle East

Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment,...

Hence then, the article about elanco receives usda approval for befrena tirnovetmab a new anti il31 monoclonal antibody injection targeting canine allergic and atopic dermatitis was published today ( Wednesday 31/12/2025 - 10:02 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis )

Also on site :

• Russian MOD shows map of Ukrainian drone attack on Putin’s residence
• From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
• I Used to Love Our Local Playground. This Common Behavior From Other Parents Is Keeping Me Away.